---
---

# 21 U.S.C., USLM ref /us/usc/t21/s353a–1

* Portions Copyright © 2016 the authors of the https://github.com/publicdocs project.
  Use of this file is subject to the NOTICE at [https://github.com/publicdocs/uscode/blob/master/NOTICE](https://github.com/publicdocs/uscode/blob/master/NOTICE)
* See the [Document Metadata](././../../../../../..//README.md) for more information.
  This file is generated from historical government data; content and/or formatting may be inaccurate and out-of-date and should not be used for official purposes.

----------
----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s353a.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s353b.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs353a%E2%80%931)

## § 353a–1. Enhanced communication

    (a) __Submissions from State boards of pharmacy__ 

    In a manner specified by the Secretary of Health and Human Services (referred to in this section as the “Secretary”), the Secretary shall receive submissions from State boards of pharmacy—

        (1) describing actions taken against compounding pharmacies, as described in subsection (b); or

        (2) expressing concerns that a compounding pharmacy may be acting contrary to [section 353a of this title][/us/usc/t21/s353a].

    (b) __Content of submissions from State boards of pharmacy__ 

    An action referred to in subsection (a)(1) is, with respect to a pharmacy that compounds drugs, any of the following:

        (1) The issuance of a warning letter, or the imposition of sanctions or penalties, by a State for violations of a State’s pharmacy regulations pertaining to compounding.

        (2) The suspension or revocation of a State-issued pharmacy license or registration for violations of a State’s pharmacy regulations pertaining to compounding.

        (3) The recall of a compounded drug due to concerns relating to the quality or purity of such drug.

    (c) __Consultation__ 

        The Secretary shall implement subsection (a) in consultation with the National Association of Boards of Pharmacy.

    (d) __Notifying State boards of pharmacy__ 

    The Secretary shall immediately notify State boards of pharmacy when—

        (1) the Secretary receives a submission under subsection (a)(1); or

        (2) the Secretary makes a determination that a pharmacy is acting contrary to [section 353a of this title][/us/usc/t21/s353a].

([Pub. L. 113–54, title I, § 105][/us/pl/113/54/s105], Nov. 27, 2013, [127 Stat. 597][/us/stat/127/597].)

 __Codification__ 

    Section was enacted as part of the Drug Quality and Security Act, and not as part of the Federal Food, Drug, and Cosmetic Act which comprises this chapter.

----------

[Previous](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s353a.md) | [Next](./../../../../../..//us/usc/t21/ch9/schV/ptA/m__us_usc_t21_s353b.md) | [Root of Title](./../../../../../../) | [Other Versions of this Document](https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs353a%E2%80%931)

----------
----------

[/us/usc/t21/s353a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs353a
[/us/usc/t21/s353a]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fusc%2Ft21%2Fs353a
[/us/pl/113/54/s105]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fpl%2F113%2F54%2Fs105
[/us/stat/127/597]: https://publicdocs.github.io/go/links?ns=uslm&ref=%2Fus%2Fstat%2F127%2F597


